Eli Lilly Acquisition Boom: $2.3B Ajax Oncology Shock
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet? Maik Kemper Editor in Chief…
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet? Maik Kemper Editor in Chief…